ArticleFrontiers in allergy2026
Persistent presumed allergic fungal rhinosinusitis during tezepelumab therapy with improvement after revision surgery: a case report.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic fungal rhinosinusitis (AFRS) is a clinically distinct subset of type 2 chronic rhinosinusitis with nasal polyps (CRSwNP), characterized by markedly elevated total IgE, fungal sensitization, and expansile disease with bony remodeling. Definitive diagnosis requires all five Bent and Kuhn criteria, including histopathological demonstration of eosinophilic mucin without tissue invasion and a positive fungal stain. Tezepelumab, a monoclonal antibody against thymic stromal lymphopoietin (anti-TSLP), has phase 3 evidence in severe CRSwNP but has not been evaluated specifically in AFRS. We report a 32-year-old woman with an AFRS-like CRSwNP phenotype, clinically and radiologically suspected but not histologically confirmed (total serum IgE 1,330 IU/mL; fungal polysensitization to Aspergillus, Alternaria, Penicillium and Candida) and severe asthma. During 11 months of tezepelumab prescribed for severe asthma rather than initiated for sinonasal disease, sinonasal disease was not controlled: the 22-item Sino-Nasal Outcome Test (SNOT-22) score remained severe (85→89/110) and imaging showed interval progression of maxillary disease, with persistence of a left posterior ethmoidal mucocele encroaching on the optic canal and orbit that had already been present on pre-biologic imaging. Revision endoscopic sinus surgery (FESS) was required; two months postoperatively the SNOT-22 improved markedly to 48/110 and asthma control improved partially (Asthma Control Test [ACT] 8→15/25). The temporal pattern is compatible with improvement following surgery rather than anti-TSLP therapy, although perioperative corticosteroids, continued medical treatment, changes in adherence and the natural course of disease may also have contributed. A single, uncontrolled observation with only two months of postoperative follow-up cannot establish that TSLP blockade is ineffective in AFRS; it does illustrate that fixed structural disease may not be addressed by biologic therapy alone. Dedicated prospective studies of anti-TSLP therapy in histologically confirmed AFRS are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.